skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma

Abstract

A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.

Inventors:
; ;
Issue Date:
Research Org.:
Univ. of Missouri, Columbia, MO (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1531467
Patent Number(s):
6,680,045
Application Number:
09/841,407
Assignee:
The Curators of the University of Missouri (Columbia, MO)
DOE Contract Number:  
FG02-93ER61661
Resource Type:
Patent
Resource Relation:
Patent File Date: 2001-04-24
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE

Citation Formats

Jurisson, Silvia S., Quinn, Thomas P., and Giblin, Michael F. Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma. United States: N. p., 2004. Web.
Jurisson, Silvia S., Quinn, Thomas P., & Giblin, Michael F. Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma. United States.
Jurisson, Silvia S., Quinn, Thomas P., and Giblin, Michael F. Tue . "Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma". United States. https://www.osti.gov/servlets/purl/1531467.
@article{osti_1531467,
title = {Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma},
author = {Jurisson, Silvia S. and Quinn, Thomas P. and Giblin, Michael F.},
abstractNote = {A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2004},
month = {1}
}

Patent:

Save / Share:

Works referenced in this record:

Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma
patent, January 2002


    Works referencing / citing this record:

    Metal abstraction peptide (MAP) tag and associated methods
    patent, March 2015


    Metal abstraction peptide (MAP) tag and associated methods
    patent, October 2012


    Metal abstraction peptide (MAP) tag and associated methods
    patent, August 2015


    Metal abstraction peptide with superoxide dismutase activity
    patent, November 2015